Is Celestica (CLS) a Buy as Wall Street Analysts Look Optimistic?
Werte in diesem Artikel
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Celestica (CLS).Celestica currently has an average brokerage recommendation (ABR) of 1.36, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 11 brokerage firms. An ABR of 1.36 approximates between Strong Buy and Buy.Of the 11 recommendations that derive the current ABR, eight are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 72.7% and 18.2% of all recommendations.Brokerage Recommendation Trends for CLSCheck price target & stock forecast for Celestica here>>>The ABR suggests buying Celestica, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.Is CLS a Good Investment?In terms of earnings estimate revisions for Celestica, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $5.05.Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Celestica. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Celestica.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Celestica, Inc. (CLS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Quelle: Zacks
Nachrichten zu Celestica Inc. (Sub Voting)
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu Celestica Inc. (Sub Voting)
Datum | Rating | Analyst | |
---|---|---|---|
17.08.2017 | Celestica Buy | Standpoint Research | |
27.01.2017 | Celestica Hold | Stifel, Nicolaus & Co., Inc. | |
18.11.2016 | Celestica Hold | Standpoint Research | |
15.01.2016 | Celestica Sector Perform | RBC Capital Markets | |
30.10.2015 | Celestica Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
17.08.2017 | Celestica Buy | Standpoint Research | |
27.01.2017 | Celestica Hold | Stifel, Nicolaus & Co., Inc. | |
30.10.2014 | Celestica Buy | Standpoint Research | |
25.10.2012 | Celestica buy | Paradigm Capital | |
17.10.2012 | Celestica sector outperform | Scotia Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
18.11.2016 | Celestica Hold | Standpoint Research | |
15.01.2016 | Celestica Sector Perform | RBC Capital Markets | |
30.10.2015 | Celestica Sector Perform | RBC Capital Markets | |
21.10.2015 | Celestica Sector Perform | RBC Capital Markets | |
07.12.2012 | Celestica sector perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
20.06.2011 | Celestica sell | Citigroup Corp. | |
22.02.2007 | Celestica reduce | UBS | |
22.07.2005 | Update Celestica Inc. (Sub Voting): Underperform | Bear Stearns |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Celestica Inc. (Sub Voting) nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen